These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31851437)

  • 1. FDA-Approved Medications to Treat Tardive Dyskinesia.
    McEvoy JP
    J Clin Psychiatry; 2019 Dec; 81(1):. PubMed ID: 31851437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valbenazine for the treatment of tardive dyskinesia.
    Seeberger LC; Hauser RA
    Expert Opin Pharmacother; 2017 Aug; 18(12):1279-1287. PubMed ID: 28699794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selecting Treatment for Patients With Tardive Dyskinesia Using Safety and Efficacy Evidence.
    McEvoy JP
    J Clin Psychiatry; 2020 Sep; 81(6):. PubMed ID: 32991793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valbenazine for the treatment of tardive dyskinesia.
    Barquero N
    Drugs Today (Barc); 2016 Dec; 52(12):665-672. PubMed ID: 28276538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tardive Dyskinesia: Treatment Update.
    Arya D; Khan T; Margolius AJ; Fernandez HH
    Curr Neurol Neurosci Rep; 2019 Aug; 19(9):69. PubMed ID: 31420757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tardive Dyskinesia: New Treatments Available.
    Limandri BJ
    J Psychosoc Nurs Ment Health Serv; 2019 May; 57(5):11-14. PubMed ID: 31042295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
    Sarva H; Henchcliffe C
    Expert Rev Clin Pharmacol; 2018 Mar; 11(3):209-217. PubMed ID: 29338466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N; Jankovic J
    Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia.
    Kim AP; Baker DE; Levien TL
    Consult Pharm; 2018 Apr; 33(4):201-209. PubMed ID: 29609698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful Treatment of Severe Tardive Dyskinesia with Valbenazine, Including a Patient's Perspective.
    Josiassen RC; Filmyer DM; Gillean J; Shah SS; Dietterich TE; Shaughnessy RA
    Am J Case Rep; 2017 Nov; 18():1185-1189. PubMed ID: 29114100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valbenazine in the treatment of tardive dyskinesia.
    Witek N; Comella C
    Neurodegener Dis Manag; 2019 Apr; 9(2):73-81. PubMed ID: 30724115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.
    Golsorkhi M; Koch J; Pedouim F; Frei K; Bondariyan N; Dashtipour K
    Tremor Other Hyperkinet Mov (N Y); 2024; 14():13. PubMed ID: 38497033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.
    Solmi M; Pigato G; Kane JM; Correll CU
    Drug Des Devel Ther; 2018; 12():1215-1238. PubMed ID: 29795977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Recommendations for Tardive Dyskinesia.
    Ricciardi L; Pringsheim T; Barnes TRE; Martino D; Gardner D; Remington G; Addington D; Morgante F; Poole N; Carson A; Edwards M
    Can J Psychiatry; 2019 Jun; 64(6):388-399. PubMed ID: 30791698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valbenazine for Tardive Dyskinesia.
    Freudenreich O; Remington G
    Clin Schizophr Relat Psychoses; 2017; 11(2):113-119. PubMed ID: 28742396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
    Khorassani F; Luther K; Talreja O
    Am J Health Syst Pharm; 2020 Jan; 77(3):167-174. PubMed ID: 31974564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2017 Jul; 71(7):. PubMed ID: 28497864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data.
    Claassen DO; Philbin M; Carroll B
    Expert Opin Pharmacother; 2019 Dec; 20(18):2209-2221. PubMed ID: 31613641
    [No Abstract]   [Full Text] [Related]  

  • 19. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.
    McIntyre RS; Calabrese JR; Nierenberg AA; Farahmand K; Yonan C; Siegert S; Burke J
    J Affect Disord; 2019 Mar; 246():217-223. PubMed ID: 30583148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deutetrabenazine in the treatment of tardive dyskinesia.
    Niemann N; Jimenez-Shahed J
    Neurodegener Dis Manag; 2019 Apr; 9(2):59-71. PubMed ID: 30702019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.